Biospherics Incorporated

Other

James P Saunders

James R Beadle

Gilbert V Levin

Lee R Zehner

Thomas J Wajda, Jr

Robert C Bozsa

A finger insert for a bowling ball which includes a socket for accepting the insert. The insert comprises an outer sleeve and an inner sleeve, wherein the outer sleeve has an outer diameter sixed to be fixedly inserted into the socket, and the inner sleeve can be rotatably and removably mounted within the outer sleeve. The inner sleeve has an interior which is sized to contain a bowler's finger.

Interchangeable and rotatable finger insert for a bowling ball

A composition and method for killing insect larvae, in particular, fly larvae, in poultry houses, manure piles, or other sites of habitation are disclosed. The composition consists of one or more C.sub.2 to C.sub.6 aliphatic carboxylic acids or alkali metal, alkaline earth, ammonia, primary, secondary, tertiary, or quaternary ammonium salts in an acceptable formulation for larvacides. The formulation may be applied dry, as an aerosol, or in aqueous or organic solvents.

Insecticidal aliphatic carboxylic acid compositons

This invention discloses edible formulations and pharmaceutical compositions containing D-tagatose and the effect of consumption of such formulations on blood level of glucose. D-Tagatose was found to be an anti-hyperglycemic agent. In addition, consumption of D-tagatose in sweetened formulations to inhibit formation of advanced glycosylation end-products in mammals is disclosed. The combination of the anti-hyperglycemic effect and the inhibition of formation of glycosylated proteins and nucleic acids make D-tagatose an ideal agent for alleviating the complications resulting from hyperglycemia, including acceleration of the aging process.

D-tagatose as anti-hyperglycemic agent

This invention discloses the usefulness of D-tagatose as a treatment for hyperglycemia, diabetes mellitus, and the inhibition of formation of advanced glycosylation end-products associated with the aging process. This invention discloses edible formulations and pharmaceutical compositions containing D-tagatose and the effect of consumption of such formulations on blood level of glucose. D-Tagatose was found to be an anti-hyperglycemic agent. In addition, consumption of D-tagatose in sweetened formulations to inhibit formation of advanced glycosylation end-products in mammals is disclosed. The combination of the anti-hyperglycemic effect and the inhibition of formation of glycosylated proteins and nucleic acids make D-tagatose an ideal agent for alleviating the complications resulting from hyperglycemia, including acceleration of the aging process.

A process is disclosed for the synthesis of D-tagatose by isomerizing a mixture containing D-galactose with a metal hydroxide in the presence of a catalyst at a relatively low temperature to form an intermediate metal hydroxide-D-tagatose complex, and then neutralizing the intermediate with acid to yield D-tagatose. The method is also suitable for the synthesis of L-tagatose from L-galactose, and for the recovery of pure tagatose from crude tagatose syrups. Whey, deproteinized whey, or lactose may be used as the raw material for the D-galactose. The lactose in such cases is hydrolyzed to D-galactose and D-glucose before the isomerization step.

Growing community of inventors

Rockville, MD, United States of America

James P Saunders